News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals
Pentixapharm welcomes CMS decision to enhance reimbursement for diagnostic radiopharmaceuticals, which could impact future streams for Ga68-PentixaFor and have broader market implications -
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Holding AG: US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor
US National Cancer Institute initiates clinical trial with PentixaFor, a new radioactive tracer, to aid in identifying adrenal tumors through PET scans, potentially benefiting patients with aldosteronism and Cushing's syndrome -
-
-
COMMUNIQUÉ DE PRESSE
Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG
Nuclear Medicine Specialist Ken Herrmann joins Pentixapharm Holding AG's Supervisory Board, bringing expertise in radiopharmaceuticals and theranostics. His appointment aims to advance oncology pipeline